Allergy Deal Boosts Astellas's Pipeline, Allows Immunomic Refocus
This article was originally published in Scrip
Executive Summary
Astellas is making good on its strategic intention to expand in vaccines and immunology, paying $300m upfront for worldwide rights to Immunomic's technology and pipeline for DNA vaccines against human allergies, in a deal that will also allow the US biotech to focus on other applications including oncology.